TL;DR
Combined in silico and experimental findings highlight hesperidin’s strong binding to key molecular targets, whereas experimental evidence also confirms its antioxidant, anti-inflammatory, and anti-apoptotic effects, supporting its potential as a disease-modifying candidate in PD therapy.
A narrative review evaluates the therapeutic potential of semaglutide in PD, focusing on its molecular mechanisms and preclinical and emerging clinical evidence, and suggests that semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in neuronal and glial cells, reducing microglial activation, neuro...
Overall, postbiotics may represent a promising therapeutic strategy for targeting neurodegenerative processes in PD, although their safety, efficacy, optimal dosing, and clinical utility require further investigations.
Overall, saponins represent a promising avenue for the development of novel neuroprotective and disease-modifying therapies for PD, and challenges such as poor bioavailability in natural sources and limited access to brain remain significant barriers to clinical translation.
NAR has demonstrated the ability to reduce amyloid-β plaque deposition, inhibit α-synuclein aggregation, preserve dopaminergic neurons, modulate immune responses in multiple sclerosis, and improve functional recovery after spinal cord injury.
The natural flavonoid Astragalin concurrently addresses three core pathological processes in PD, namely dopaminergic neuron degeneration, α-synucleinopathy, and neuroinflammation, through coordinated modulation of interconnected molecular pathways.
Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and cerebral ischemia, represent an escalating global health crisis with limited effective therapies. The multifactorial pathogenesis of these disorders, encompassing protein aggregation, oxidative stress, neuroinflammation, and m...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
